Updates to the ESMO CLL clinical practice guidelines: implications for frontline treatment
Episode 288 of the VJHemOnc Podcast podcast, hosted by VJHemOnc, titled "Updates to the ESMO CLL clinical practice guidelines: implications for frontline treatment" was published on April 25, 2025 and runs 34 minutes.
April 25, 2025 ·34m · VJHemOnc Podcast
Summary
In this VJHemOnc podcast, experts Barbara Eichhorst, MD, University Hospital Cologne, Cologne, Germany, Lydia Scarfò, MD, Vita-Salute San Raffaele University and IRCCS San Raffaele Scientific Institute, Milan, Italy, and Anna Schuh, MD, PhD, University of Oxford, Oxford, UK, provide insights into the latest updates to the ESMO clinical practice guidelines for chronic lymphocytic leukemia (CLL). They cover key topics such as diagnostic advancements, frontline treatment strategies based on IGHV mutational status, the role of double oral combinations, the importance of measurable residual disease (MRD)-guided treatment, and the debate between time-limited and continuous regimens.
Episode Description
In this VJHemOnc podcast, experts Barbara Eichhorst, MD, University Hospital Cologne, Cologne, Germany, Lydia Scarfò, MD, Vita-Salute San Raffaele University and IRCCS San Raffaele Scientific Institute, Milan, Italy, and Anna Schuh, MD, PhD, University of Oxford, Oxford, UK, provide insights into the latest updates to the ESMO clinical practice guidelines for chronic lymphocytic leukemia (CLL). They cover key topics such as diagnostic advancements, frontline treatment strategies based on IGHV mutational status, the role of double oral combinations, the importance of measurable residual disease (MRD)-guided treatment, and the debate between time-limited and continuous regimens.
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.